BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bajpai M, Maheshwari A, Dogra V, Kumar S, Gupta E, Kale P, Saluja V, Thomas SS, Trehanpati N, Bihari C, Agarwal R, Bharti P, Shankar P, Hussain J, Chhabra K, Gupta A, Narayanan A, Agarwal S, Jain S, Bhardwaj A, Kumar G, Yadav BK, Sarin SK. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ Open 2022;12:e055189. [PMID: 35387813 DOI: 10.1136/bmjopen-2021-055189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, Paneth NS, Sullivan DJ, Morkeberg OH, Wright RS, Fairweather D, Bruno KA, Shoham S, Bloch EM, Focosi D, Henderson JP, Juskewitch JE, Pirofski L, Grossman BJ, Tobian AA, Franchini M, Ganesh R, Hurt RT, Kay NE, Parikh SA, Baker SE, Buchholtz ZA, Buras MR, Clayburn AJ, Dennis JJ, Diaz Soto JC, Herasevich V, Klompas AM, Kunze KL, Larson KF, Mills JR, Regimbal RJ, Ripoll JG, Sexton MA, Shepherd JR, Stubbs JR, Theel ES, van Buskirk CM, van Helmond N, Vogt MN, Whelan ER, Wiggins CC, Winters JL, Casadevall A, Joyner MJ. Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis.. [DOI: 10.1101/2023.01.11.23284347] [Reference Citation Analysis]
2 Denkinger CM, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier JF, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJGT, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse PR, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad MA, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz HM, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich HG, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-Tidow C. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer 2023;4:96-107. [PMID: 36581734 DOI: 10.1038/s43018-022-00503-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Körper S, Grüner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, Zacharowski K, Spieth P, Tonn T, Rosenberger P, Paul G, Pilch J, Schwäble J, Bakchoul T, Thiele T, Knörlein J, Dollinger MM, Krebs J, Bentz M, Corman VM, Kilalic D, Schmidtke-Schrezenmeier G, Lepper PM, Ernst L, Wulf H, Ulrich A, Weiss M, Kruse JM, Burkhardt T, Müller R, Klüter H, Schmidt M, Jahrsdörfer B, Lotfi R, Rojewski M, Appl T, Mayer B, Schnecko P, Seifried E, Schrezenmeier H. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J Clin Invest 2022;132. [PMID: 36326824 DOI: 10.1172/JCI163657] [Reference Citation Analysis]
4 Kiss-Dala N, Szabo BG, Lakatos B, Reti M, Szlavik J, Valyi-Nagy I. Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. Geroscience 2022;44:2427-45. [PMID: 36367599 DOI: 10.1007/s11357-022-00683-4] [Reference Citation Analysis]
5 Denkinger C, Janssen M, Schäkel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J, Merle U, Weigand MA, Nusshag C, Bullinger L, Schrezenmeier J, Bornhäuser M, Alakel N, Witzke O, Wolf T, Vehreschild MJ, Schmiedel S, Addo MM, Herth F, Kreuter M, Tepasse P, Hertenstein B, Hänel M, Morgner A, Kiehl M, Hopfer O, Wattad M, Schimanski CC, Celik C, Pohle T, Ruhe M, Kern WV, Schmitt A, Lorenz H, Souto-carneiro M, Gaeddert M, Halama N, Meuer S, Kräusslich H, Müller B, Schnitzler P, Parthé S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk RF, Müller-tidow C. Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial.. [DOI: 10.1101/2022.10.10.22280850] [Reference Citation Analysis]
6 Villanueva C, Neyra I, Sagastegui A, Chunga A, Oyanguren M, Guillermo-roman M, Soto-ordoñez S, Maguiña JL, Hurtado-roca Y, Soto-becerra P, Araujo-castillo RV. Efficacy and safety of convalescent plasma versus standard care in hospitalized patients with COVID-19 from the Peruvian Social Security Health System: open-label, randomized, controlled clinical trial.. [DOI: 10.1101/2022.09.21.22280195] [Reference Citation Analysis]
7 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022;:e0175122. [PMID: 36135380 DOI: 10.1128/mbio.01751-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Battaglini D, Cruz F, Robba C, Pelosi P, Rocco PRM. Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opin Investig Drugs 2022. [PMID: 36047644 DOI: 10.1080/13543784.2022.2120801] [Reference Citation Analysis]
9 Rojas M, Rodríguez Y, Hernández JC, Díaz-coronado JC, Vergara JAD, Vélez VP, Mancilla JP, Araujo I, Yepes JT, Ricaurte OB, Pardo-oviedo JM, Monsalve DM, Acosta-ampudia Y, Ramírez-santana C, García PG, Landinez LA, Correales LD, Grass JS, Pérez CR, López GS, Mateus N, Mancera L, Devia RR, Orjuela JE, Parra-moreno CR, Buitrago AA, Ordoñez IE, Osorio CF, Ballesteros N, Patiño LH, Castañeda S, Muñoz M, Ramírez JD, Bastard P, Gervais A, Bizien L, Casanova J, Camacho B, Gallo JE, Gómez O, Rojas-villarraga A, Pérez CE, Manrique R, Mantilla RD, Anaya J. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07560-7] [Reference Citation Analysis]
10 Maheshwari A, Varshney M, Bajpai M, Raizada N, Sharma T. An Exploratory Study of the Differences in Attitudes and Motives Regarding COVID-19 Plasma Donation. AML 2022;29:14. [DOI: 10.15388/amed.2022.29.1.14] [Reference Citation Analysis]
11 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study.. [DOI: 10.1101/2022.04.29.22274387] [Reference Citation Analysis]